

Prescribing of flupirtine in IMS Disease Analyser in Germany (Flupirtine drug utilisation in Germany)

First published: 03/03/2020

Last updated: 03/03/2020

Study

Finalised

Administrative details

EU PAS number

EUPAS33919

Study ID

33920

DARWIN EU® study

No

Study countries

 Germany

Study description

The study identifies specialist categories that prescribe flupirtine. The age and gender distribution of patients is analysed among flupirtine prescriptions. The total number of patients with a prescription, and the number of patients with a first prescription for flupirtine is then analysed over time between 2010 and June 2017 (yearly and halfyearly) in GP and orthopedic practices.

Study status

Finalised

Research institutions and networks

Institutions

European Medicines Agency (EMA)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Karin Hedenmalm karin.hedenmalm@ema.europa.eu

Study contact

karin.hedenmalm@ema.europa.eu

Primary lead investigator

Karin Hedenmalm

Study timelines

Date when funding contract was signed

Planned: 13/07/2017

Actual: 13/07/2017

Study start date

Planned: 29/08/2017

Actual: 29/08/2017

Data analysis start date

Planned: 29/08/2017

Actual: 29/08/2017

Date of final study report

Planned: 29/08/2017

Actual: 29/08/2017

Sources of funding

- EMA

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Data collection methods:

Secondary use of data

Main study objective:

To study prescribing of flupirtine by prescriber category, gender, age, and time period.

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

Population studied

Short description of the study population

Patients with a prescription for flupirtine.

Age groups

- Preterm newborn infants (0 - 27 days)
 - Term newborn infants (0 - 27 days)
 - Infants and toddlers (28 days - 23 months)
 - Children (2 to < 12 years)
 - Adolescents (12 to < 18 years)
 - Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

200000

Study design details

Data analysis plan

Number of patients and number of prescriptions

Documents

Study results

[Flupirtine.pdf](#) (253.24 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Electronic healthcare records \(EHR\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No